Stockreport

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech Inc. - Common Shares  (ONCY) 
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com
PDF 33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%Translational analysis shows pelareorep [Read more]